Huntingtin cleavage product A forms in neurons and is reduced by gamma-secretase inhibitors

Molecular Neurodegeneration

Volumn 5, Issue 1, 2010, Pages

  Kegel, Kimberly B ^a   Sapp, Ellen ^a   Alexander, Jonathan ^a   Reeves, Patrick ^a   Bleckmann, Dorothee ^b   Sobin, Linsday ^a   Masso, Nicholas ^a   Valencia, Antonio ^a   Jeong, Hyunkyung ^a   Krainc, Dimitri ^a   Palacino, James ^c   Curtis, Daniel ^c   Kuhn, Rainer ^b   Betschart, Claudia ^b   Sena Esteves, Miguel ^a   Aronin, Neil ^d   Paganetti, Paolo ^b   Difiglia, Marian ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; CATHEPSIN E; CLEAVAGE PRODUCT A; CLEAVAGE PRODUCT B; DAPTOMYCIN; GAMMA SECRETASE INHIBITOR; HUNTINGTIN; IMATINIB; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; P1 N031; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN CELL; CELL NUCLEUS; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; CYTOPLASM; ENZYME ACTIVITY; FEMALE; GENE SILENCING; HUNTINGTON CHOREA; LENTIVIRINAE; MOUSE; NERVE CELL; NERVE CELL CULTURE; NONHUMAN;

ADENO-ASSOCIATED VIRUS; LENTIVIRUS;

EID: 78650035000     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-5-58     Document Type: Article

References (62)

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993 72 971 983 10.1016/0092-8674(93)90585-E 8458085
2. Characterization of huntingtin pathologic fragments in human Huntington disease, transgenic mice, and cell models. G Schilling A Klevytska AT Tebbenkamp K Juenemann J Cooper V Gonzales H Slunt M Poirer CA Ross DR Borchelt, J Neuropathol Exp Neurol 2007 66 313 320 10.1097/nen.0b013e318040b2c8 17413322
3. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. ZX Yu SH Li J Evans A Pillarisetti H Li XJ Li, J Neurosci 2003 23 2193 2202 12657678
4. Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. H Zhou F Cao Z Wang ZX Yu HP Nguyen J Evans SH Li XJ Li, J Cell Biol 2003 163 109 118 10.1083/jcb. 200306038 14557250
5. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. SW Davies M Turmaine BA Cozens M DiFiglia AH Sharp CA Ross E Scherzinger EE Wanker L Mangiarini GP Bates, Cell 1997 90 537 548 10.1016/S0092-8674(00)80513-9 9267033
6. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. M DiFiglia E Sapp KO Chase SW Davies GP Bates JP Vonsattel N Aronin, Science 1997 277 1990 1993 10.1126/science.277.5334.1990 9302293
7. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. CA Gutekunst SH Li H Yi JS Mulroy S Kuemmerle R Jones D Rye RJ Ferrante SM Hersch XJ Li, J Neurosci 1999 19 2522 2534 10087066
8. The influence of huntingtin protein size on nuclear localization and cellular toxicity. AS Hackam R Singaraja CL Wellington M Metzler K McCutcheon T Zhang M Kalchman MR Hayden, J Cell Biol 1998 141 1097 1105 10.1083/jcb.141.5. 1097 9606203
9. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. F Saudou S Finkbeiner D Devys ME Greenberg, Cell 1998 95 55 66 10.1016/S0092-8674(00)81782-1 9778247
10. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. E Scherzinger R Lurz M Turmaine L Mangiarini B Hollenbach R Hasenbank GP Bates SW Davies H Lehrach EE Wanker, Cell 1997 90 549 558 10.1016/S0092-8674(00)80514-0 9267034
11. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. M DiFiglia M Sena-Esteves K Chase E Sapp E Pfister M Sass J Yoder P Reeves RK Pandey KG Rajeev M Manoharan DW Sah PD Zamore N Aronin, Proc Natl Acad Sci USA 2007 104 17204 17209 10.1073/pnas.0708285104 17940007
12. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. G Schilling MW Becher AH Sharp HA Jinnah K Duan JA Kotzuk HH Slunt T Ratovitski JK Cooper NA Jenkins NG Copeland DL Price CA Ross DR Borchelt, Hum Mol Genet 1999 8 397 407 10.1093/hmg/8.3.397 9949199
13. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. GA Laforet E Sapp K Chase C McIntyre FM Boyce M Campbell BA Cadigan L Warzecki DA Tagle PH Reddy C Cepeda CR Calvert ES Jokel GJ Klapstein MA Ariano MS Levine M DiFiglia N Aronin, J Neurosci 2001 21 9112 9123 11717344
14. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. LB Menalled JD Sison Y Wu M Olivieri XJ Li H Li S Zeitlin MF Chesselet, J Neurosci 2002 22 8266 8276 12223581
15. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. JG Hodgson N Agopyan CA Gutekunst BR Leavitt F LePiane R Singaraja DJ Smith N Bissada K McCutcheon J Nasir L Jamot XJ Li ME Stevens E Rosemond JC Roder AG Phillips EM Rubin SM Hersch MR Hayden, Neuron 1999 23 181 192 10.1016/S0896-6273(00)80764-3 10402204
16. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. M Gray DI Shirasaki C Cepeda VM Andre B Wilburn XH Lu J Tao I Yamazaki SH Li YE Sun XJ Li MS Levine XW Yang, J Neurosci 2008 28 6182 6195 10.1523/JNEUROSCI.0857-08.2008 18550760
17. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. EJ Slow RK Graham AP Osmand RS Devon G Lu Y Deng J Pearson K Vaid N Bissada R Wetzel BR Leavitt MR Hayden, Proc Natl Acad Sci USA 2005 102 11402 11407 10.1073/pnas.0503634102 16076956
18. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. CL Wellington LM Ellerby CA Gutekunst D Rogers S Warby RK Graham O Loubser J van Raamsdonk R Singaraja YZ Yang J Gafni D Bredesen SM Hersch BR Leavitt S Roy DW Nicholson MR Hayden, J Neurosci 2002 22 7862 7872 12223539
19. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. YJ Kim Y Yi E Sapp Y Wang B Cuiffo KB Kegel ZH Qin N Aronin M DiFiglia, Proc Natl Acad Sci USA 2001 98 12784 12789 10.1073/pnas.221451398 11675509
20. Huntingtin cleavage induced by thrombin in vitro. F Lin J Wu Y Wang Z Qin, Acta Biochim Biophys Sin (Shanghai) 2007 39 15 18 17213954
21. Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease. JP Miller J Holcomb I Al-Ramahi M de Haro J Gafni N Zhang E Kim M Sanhueza C Torcassi S Kwak J Botas RE Hughes LM Ellerby, Neuron 2010 67 199 212 10.1016/j.neuron.2010.06.021 20670829
22. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. RK Graham Y Deng EJ Slow B Haigh N Bissada G Lu J Pearson J Shehadeh L Bertram Z Murphy SC Warby CN Doty S Roy CL Wellington BR Leavitt LA Raymond DW Nicholson MR Hayden, Cell 2006 125 1179 1191 10.1016/j.cell.2006.04.026 16777606
23. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. A Lunkes KS Lindenberg L Ben-Haiem C Weber D Devys GB Landwehrmeyer JL Mandel Y Trottier, Mol Cell 2002 10 259 269 10.1016/S1097-2765(02)00602-0 12191472
24. Lysosomal proteases are involved in generation of N-terminal huntingtin fragments. YJ Kim E Sapp BG Cuiffo L Sobin J Yoder KB Kegel ZH Qin P Detloff N Aronin M DiFiglia, Neurobiol Dis 2006 22 346 356 10.1016/j.nbd.2005.11.012 16423528
25. Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. CL Benn C Landles H Li AD Strand B Woodman K Sathasivam SH Li S Ghazi-Noori E Hockly SM Faruque JH Cha PT Sharpe JM Olson XJ Li GP Bates, Hum Mol Genet 2005 14 3065 3078 10.1093/hmg/ddi340 16183657
26. Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum. LM Mende-Mueller T Toneff SR Hwang MF Chesselet VY Hook, J Neurosci 2001 21 1830 1837 11245667
27. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. N Deglon JL Tseng JC Bensadoun AD Zurn Y Arsenijevic L Pereira de Almeida R Zufferey D Trono P Aebischer, Hum Gene Ther 2000 11 179 190 10.1089/10430340050016256 10646649
28. Immortalized murine striatal neuronal cell lines expressing dopamine receptors and cholinergic properties. MS Wainwright BD Perry LA Won KL O'Malley WY Wang ME Ehrlich A Heller, J Neurosci 1995 15 676 688 7823171
29. Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. KB Kegel M Kim E Sapp C McIntyre JG Castano N Aronin M DiFiglia, J Neurosci 2000 20 7268 7278 11007884
30. Gleevec inhibits beta-amyloid production but not Notch cleavage. WJ Netzer F Dou D Cai D Veach S Jean Y Li WG Bornmann B Clarkson H Xu P Greengard, Proc Natl Acad Sci USA 2003 100 12444 12449 10.1073/pnas.1534745100 14523244
31. gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. PC Fraering W Ye MJ LaVoie BL Ostaszewski DJ Selkoe MS Wolfe, J Biol Chem 2005 280 41987 41996 10.1074/jbc.M501368200 16236717
32. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. GT Wong D Manfra FM Poulet Q Zhang H Josien T Bara L Engstrom M Pinzon-Ortiz JS Fine HJ Lee L Zhang GA Higgins EM Parker, J Biol Chem 2004 279 12876 12882 10.1074/jbc.M311652200 14709552
33. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. HF Dovey V John JP Anderson LZ Chen P de Saint Andrieu LY Fang SB Freedman B Folmer E Goldbach EJ Holsztynska KL Hu KL Johnson-Wood SL Kennedy D Kholodenko JE Knops LH Latimer M Lee Z Liao IM Lieberburg RN Motter LC Mutter J Nietz KP Quinn KL Sacchi PA Seubert GM Shopp ED Thorsett JS Tung J Wu S Yang CT Yin DB Schenk PC May LD Altstiel MH Bender LN Boggs TC Britton JC Clemens DL Czilli DK Dieckman-McGinty JJ Droste KS Fuson BD Gitter PA Hyslop EM Johnstone WY Li SP Little TE Mabry FD Miller JE Audia, J Neurochem 2001 76 173 181 10.1046/j.1471-4159.2001.00012.x 11145990
34. Association of active gamma-secretase complex with lipid rafts. Y Urano I Hayashi N Isoo PC Reid Y Shibasaki N Noguchi T Tomita T Iwatsubo T Hamakubo T Kodama, J Lipid Res 2005 46 904 912 10.1194/jlr.M400333-JLR200 15716592
35. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. YM Li M Xu MT Lai Q Huang JL Castro J DiMuzio-Mower T Harrison C Lellis A Nadin JG Neduvelil RB Register MK Sardana MS Shearman AL Smith XP Shi KC Yin JA Shafer SJ Gardell, Nature 2000 405 689 694 10.1038/35015085 10864326
36. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease. A Valencia PB Reeves E Sapp X Li J Alexander KB Kegel K Chase N Aronin M DiFiglia, J Neurosci Res 2010 88 179 190 10.1002/jnr.22184 19642201
37. Aberrant Rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington's disease. X Li A Valencia E Sapp N Masso J Alexander P Reeves KB Kegel N Aronin M Difiglia, J Neurosci 2010 30 4552 4561 10.1523/JNEUROSCI.5865-09.2010 20357106
38. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. C Landles K Sathasivam A Weiss B Woodman H Moffitt S Finkbeiner B Sun J Gafni LM Ellerby Y Trottier WG Richards A Osmand P Paganetti GP Bates, J Biol Chem 285 8808 8823 10.1074/jbc.M109.075028 20086007
39. Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease. A Weiss D Abramowski M Bibel R Bodner V Chopra M DiFiglia J Fox K Kegel C Klein S Grueninger S Hersch D Housman E Regulier HD Rosas M Stefani S Zeitlin G Bilbe P Paganetti, Anal Biochem 2009 395 8 15 10.1016/j.ab.2009.08.001 19664996
40. Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons. S Tydlacka CE Wang X Wang S Li XJ Li, J Neurosci 2008 28 13285 13295 10.1523/JNEUROSCI.4393-08.2008 19052220
41. Gamma-secretase exists on the plasma membrane as an intact complex that accepts substrates and effects intramembrane cleavage. JH Chyung DM Raper DJ Selkoe, J Biol Chem 2005 280 4383 4392 10.1074/jbc.M409272200 15569674
42. Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements. ML Hemming JE Elias SP Gygi DJ Selkoe, PLoS Biol 2008 6 257 10.1371/journal.pbio.0060257 18942891
43. Polyglutamine expansion in huntingtin alters its interaction with phospholipids. KB Kegel E Sapp J Alexander A Valencia P Reeves X Li N Masso L Sobin N Aronin M DiFiglia, J Neurochem 2009 110 1585 1597 10.1111/j.1471-4159. 2009.06255.x 19566678
44. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. RS Atwal J Xia D Pinchev J Taylor RM Epand R Truant, Hum Mol Genet 2007 16 2600 2615 10.1093/hmg/ddm217 17704510
45. Interaction of huntingtin fragments with brain membranes - clues to early dysfunction in Huntington's disease. J Suopanki C Gotz G Lutsch J Schiller P Harjes A Herrmann EE Wanker, J Neurochem 2006 96 870 884 10.1111/j.1471-4159. 2005.03620.x 16405500
46. Polyglutamine expansion in huntingtin increases its insertion into lipid bilayers. KB Kegel V Schewkunow E Sapp N Masso EE Wanker M DiFiglia WH Goldmann, Biochem Biophys Res Commun 2009 387 472 475 10.1016/j.bbrc.2009.07.039 19607813
47. The channel hypothesis of Huntington's disease. BL Kagan Y Hirakura R Azimov R Azimova, Brain Res Bull 2001 56 281 284 10.1016/S0361-9230(01)00654-2 11719262
48. Presenilin: running with scissors in the membrane. DJ Selkoe MS Wolfe, Cell 2007 131 215 221 10.1016/j.cell.2007.10.012 17956719
49. Presenilins and the gamma-secretase: still a complex problem. DH Small DW Klaver L Foa, Mol Brain 2010 3 7 10.1186/1756-6606-3-7 20181106
50. Mutant protein in Huntington disease is resistant to proteolysis in affected brain. RB Dyer CT McMurray, Nat Genet 2001 29 270 278 10.1038/ng745 11600884
51. Intramembrane proteolysis by signal peptide peptidases: a comparative discussion of GXGD-type aspartyl proteases. R Fluhrer H Steiner C Haass, J Biol Chem 2009 284 13975 13979 10.1074/jbc.R800040200 19189970
52. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. G He W Luo P Li C Remmers WJ Netzer J Hendrick K Bettayeb M Flajolet F Gorelick LP Wennogle P Greengard, Nature 2010 467 95 98 10.1038/nature09325 20811458
53. Direct and potent regulation of gamma-secretase by its lipid microenvironment. P Osenkowski W Ye R Wang MS Wolfe DJ Selkoe, J Biol Chem 2008 283 22529 22540 10.1074/jbc.M801925200 18539594
54. Contribution of gamma-secretase to calcium-mediated cell death. YH Choi AR Gwon HY Jeong JS Park SH Baik TV Arumugam DG Jo, Neurosci Lett 2010 469 425 428 10.1016/j.neulet.2009.12.043 20035833
55. Peptidomimetic probes and molecular modeling suggest that Alzheimer's gamma-secretase is an intramembrane-cleaving aspartyl protease. MS Wolfe W Xia CL Moore DD Leatherwood B Ostaszewski T Rahmati IO Donkor DJ Selkoe, Biochemistry 1999 38 4720 4727 10.1021/bi982562p 10200159
56. Age-related changes in activities and localizations of cathepsins D, E, B, and L in the rat brain tissues. H Nakanishi K Tominaga T Amano I Hirotsu T Inoue K Yamamoto, Exp Neurol 1994 126 119 128 10.1006/exnr.1994.1048 8157122
57. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. MS Wolfe W Xia BL Ostaszewski TS Diehl WT Kimberly DJ Selkoe, Nature 1999 398 513 517 10.1038/19077 10206644
58. Autophagy regulates the processing of amino terminal huntingtin fragments. ZH Qin Y Wang KB Kegel A Kazantsev BL Apostol LM Thompson J Yoder N Aronin M DiFiglia, Hum Mol Genet 2003 12 3231 3244 10.1093/hmg/ddg346 14570716
59. N-terminal proteolysis of full-length mutant huntingtin in an inducible PC12 cell model of Huntington's disease. T Ratovitski M Nakamura J D'Ambola E Chighladze Y Liang W Wang R Graham MR Hayden DR Borchelt RR Hirschhorn CA Ross, Cell Cycle 2007 6 2970 2981 10.4161/cc.6.23.4992 18156806
60. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. C Landles K Sathasivam A Weiss B Woodman H Moffitt S Finkbeiner B Sun J Gafni LM Ellerby Y Trottier WG Richards A Osmand P Paganetti GP Bates, J Biol Chem 2010 285 8808 8823 10.1074/jbc.M109.075028 20086007
61. Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. S Hanessian H Yun Y Hou G Yang M Bayrakdarian E Therrien N Moitessier S Roggo S Veenstra M Tintelnot-Blomley JM Rondeau C Ostermeier A Strauss P Ramage P Paganetti U Neumann C Betschart, J Med Chem 2005 48 5175 5190 10.1021/jm050142+ 16078837
62. Huntingtin associates with acidic phospholipids at the plasma membrane. KB Kegel E Sapp J Yoder B Cuiffo L Sobin YJ Kim ZH Qin MR Hayden N Aronin DL Scott G Isenberg WH Goldmann M Difiglia, J Biol Chem 2005 280 36464 36473 10.1074/jbc.M503672200 16085648